“Quo vadis, medicina?” Serious doubts about where we’re heading: regulations, influence of “big pharma” and the industry, and the shackles of “level one evidence” studies

Ferenc KuhnHelen Keller Foundation for Research and Education, Birmingham, AL, USA;International Society of Ocular Trauma, Birmingham, AL, USACorrespondence[email protected]
View further author information

Judit KuhnUNC Rex Healthcare, Raleigh, NC, USAView further author information

References

Fields RI. Why is health care regulation so complex? PT. 2008;33:607–608.
PubMedGoogle Scholar
Gunderman R, Kanter SL. Educating physicians to lead hospitals. Acad Med. 2009;84:1348–1351.
PubMed Web of Science ®Google Scholar
Chemical and engineering news. 2014 Nov 20.
Google Scholar
CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364:1897–1908.
PubMed Web of Science ®Google Scholar
Holmes D, Murray SJ, Perron A, et al. Deconstructing the evidence-based discourse in health sciences: truth, power and fascism. Int J Evid Based Healthc. 2006;4:180–186.
PubMedGoogle Scholar
Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995;113:1479–1496.
PubMedGoogle Scholar
Kuhn F, Gini G. Vitrectomy for endophthalmitis. Ophthalmology. 2006;113:714.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

“Quo vadis, medicina?” Serious doubts about where we’re heading: regulations, influence of “big pharma” and the industry, and the shackles of “level one evidence” studies

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

“Quo vadis, medicina?” Serious doubts about where we’re heading: regulations, influence of “big pharma” and the industry, and the shackles of “level one evidence” studies

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date